Unknown

Dataset Information

0

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.


ABSTRACT: Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase. Such mutations are associated with a poor prognosis and a high propensity to relapse after remission. FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD(+) acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for additional therapeutic targets. We show that the US Food and Drug Administration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells. The effect is specific for FLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of the FLT3 and PIM1 genes, another important leukemogenic driver. There CDK6 regulates transcription in a kinase-dependent manner. Of potential clinical relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity. Simultaneously targeting two critical signaling nodes in leukemogenesis could represent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.

SUBMITTER: Uras IZ 

PROVIDER: S-EPMC4920675 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Uras Iris Z IZ   Walter Gina J GJ   Scheicher Ruth R   Bellutti Florian F   Prchal-Murphy Michaela M   Tigan Anca S AS   Valent Peter P   Heidel Florian H FH   Kubicek Stefan S   Scholl Claudia C   Fröhling Stefan S   Sexl Veronika V  

Blood 20160420 23


Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase. Such mutations are associated with a poor prognosis and a high propensity to relapse after remission. FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD(+) acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for additional therapeutic targets. We show that t  ...[more]

Similar Datasets

| S-EPMC5053879 | biostudies-literature
| S-EPMC7138400 | biostudies-literature
| S-EPMC4987127 | biostudies-literature
| S-EPMC5045383 | biostudies-literature
| S-EPMC5519068 | biostudies-other
| S-EPMC8075860 | biostudies-literature
| S-EPMC6321303 | biostudies-literature
| S-EPMC6880894 | biostudies-literature
| S-EPMC2384125 | biostudies-literature
| S-EPMC9817690 | biostudies-literature